Ching Kim Tye
Head of DP Platform and Early Clinical Development Sanofi
Dr. Ching Kim Tye brings two decades of pharmaceutical R&D expertise, specializing in formulation and drug delivery systems. As Head of Drug Product Platform and Early Clinical Development at Sanofi, she leads innovation in mRNA-LNP technology development.
Currently, Kim spearheads the development of next-generation LNPs with enhanced potency and thermostability for both intramuscular and intranasal delivery routes, advancing candidates into Phase 1 clinical trials. Her comprehensive experience spans from early research through late-stage development, including work with diverse therapeutic modalities—proteins and small molecules at CSL, Pfizer, and Eli Lilly.
Seminars
Wednesday 8th April 2026
Panel Discussion: Overcoming Clinical Bottlenecks in LNP Development by Streamlining Processes for Advancing Safer Drug Products to Patients
10:00 am
- What are the most crucial technical challenges in translating LNP formulations from preclinic to human studies?
- As the field moves from early clinical programs to commercialization, what are the key challenges in translating LNP formulations from small-scale development into robust, large-scale manufacturing processes?
- How to optimize the dosing strategies for LNPs to ensure safe and effective therapeutics?
